The biomarker section is witnessing rapid technological advancements and higher demand for individualized drugs. As a result, to be certain patient entry to these new technologies, a reimbursement framework needs to be labored upon to meet the transforming market state of affairs.Competitive landscape reporting: market leaders and critical gamers,